本文介绍我所新抗室试制的Aclacinom-y cin A(ACM-A)体外、体内抗肿瘤活性,并与进口样品进行了比较。在体外,用~3H-TdR、~3HUR掺入试验法表明ACM-A在浓度为3.25～1.25μ/ml时对C_(1210)白血病细胞生长抑制达61～95％(~3H-TdR)、81～96％(~3H-uR);对P388白血病细胞生长抑制,当浓度为0.05～0.2μ/ml时为50～98％,其作用强度与日本临床试用ACM-A样品相当。在体内,我们用常规方法,考察了ACM-A腹腔注 This article describes the in vitro and in vivo antitumor activity of Aclacinom-y cin A (ACM-A) prepared in our new anti-cancer laboratory and compared with imported samples. In vitro, ~ 3H-TdR and ~ 3HUR incorporation assays showed that ACM-A inhibited the growth of C 1210 leukemia cells by 61-95% (~ 3H-TdR) at the concentration of 3.25-1.25 μL / ml, 81 ~ 96% (~ 3H-uR). The inhibitory effect on the growth of P388 leukemia cells was 50% ~ 98% at the concentration of 0.05 ~ 0.2μ / ml, which was comparable to that of the Japanese clinical trial ACM-A. In vivo, we examined the ACM-A intraperitoneal injection in a routine manner